HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 83.8%

Neg 0% Neu 83.8% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.